Patents Assigned to Wyeth
  • Patent number: 7354927
    Abstract: This invention provides 6H-[1]benzopyrano[4,3-b]quinoline compounds having the formula I: The invention further provides compositions including the compounds, methods for the use of the compounds, and methods of preparation of the compounds.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: April 8, 2008
    Assignee: Wyeth
    Inventor: An T. Vu
  • Patent number: 7354915
    Abstract: Compounds having the structure of formula I are provided. In formula I, R1 is H, OH, substituted or unsubstituted C1 to C3 alkyl, C1 to C3 perfluoroalkyl, or COR6; R6 is H, substituted or unsubstituted C1 to C4 alkyl, aryl, substituted or unsubstituted C1 to C4 alkoxy, substituted or unsubstituted C1 to C3 aminoalkyl; R2 and R3 are H, substituted or unsubstituted C1 to C6 alkyl, C1 to C6 perfluoroalkyl, substituted or unsubstituted C2 to C6 alkenyl, substituted or unsubstituted C2 to C6 alkynyl, substituted or unsubstituted C3 to C6 cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclic; or R2 and R3 are fused to form spirocyclic rings; R4 is NHR7, OR7, NHSO2R7, or OSO2R7; Q is O, S, NR8, or CR9R10; or a pharmaceutically acceptable salt, ester, or prodrug thereof.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: April 8, 2008
    Assignee: Wyeth
    Inventors: Puwen Zhang, Jeffrey Kern
  • Publication number: 20080081910
    Abstract: The present invention provides cycloalkylfused indole, benzothiophene, benzofuran, and indene derivatives, and methods for using them to, for example, treat, prevent and/or ameliorate central nervous system diseases by antagonizing 5-HT1A receptors and modulating serotonin levels.
    Type: Application
    Filed: October 11, 2007
    Publication date: April 3, 2008
    Applicant: Wyeth
    Inventors: Annmarie Sabb, Robert Vogel, Gary Stack, Deborah Evrard, Amedeo Failli, Lalitha Krishnan, Anita Chan, Jianxin Ren, Charles Guinosso, Reinhardt Baudy, Jean Sze, Yanfang Li, Charles Stanton, Antonia Nikitenko
  • Publication number: 20080081792
    Abstract: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell.
    Type: Application
    Filed: November 30, 2006
    Publication date: April 3, 2008
    Applicant: Wyeth
    Inventors: Catherine Pachuk, Chandrasekhar Satishchandran
  • Publication number: 20080081356
    Abstract: An improved system for large scale production of glycoproteins in cell culture is provided. In accordance with the present invention, cells expressing a glycoprotein are grown in media that contain manganese at a concentration of between approximately 10 and 600 nM. The use of such a system allows production of a glycoprotein with an increased glycosylation pattern and/or a glycosylation pattern that more accurately reflects the glycosylation pattern of the naturally occurring glycoprotein. A glycoprotein expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical compositions.
    Type: Application
    Filed: July 11, 2007
    Publication date: April 3, 2008
    Applicant: Wyeth
    Inventors: Daniel Lasko, Stephan Koza
  • Publication number: 20080081366
    Abstract: A lyophilized polynucleotide composition contains at least one polynucleotide and at least one cryoprotectant, wherein the ratio of the polynucleotide to cryoprotectant is from about 0.001 to about 1.0 part by weight polynucleotide per 1.0 part by weight of the cryoprotectant. This composition also contains from about 0.5 weight percent to about (6) weight percent water, based on the total weight of the final lyophilized polynucleotide composition. The polynucleotide composition of this invention is characterized by enhanced stability, in that it retains at least 90% supercoil over a time period of at least (10) days at a temperature of about 37° C. The lyophilized polynucleotide composition also has improved solubility. An improved process for lyophilization of polynucleotides employs a specific primary drying cycle, that results in the above-described stable, lyophilized polynucleotide composition.
    Type: Application
    Filed: August 24, 2007
    Publication date: April 3, 2008
    Applicant: Wyeth
    Inventors: Shankar Musunuri, Patrick DeLuca
  • Patent number: 7351726
    Abstract: The present invention relates generally to substituted oxadiazolidinediones and methods of using them.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: April 1, 2008
    Assignee: Wyeth
    Inventors: Hassan Mahmoud Elokdah, Michael Sotirios Malamas
  • Patent number: 7351743
    Abstract: The present invention provides therapeutically useful substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: April 1, 2008
    Assignee: Wyeth
    Inventors: Stanley M. Goldin, James B. Fischer, Andrew Gannett Knapp, N. Laxma Reddy, David Berlove, Graham J. Durant, Subbarao Katragadda, Lain-Yen Hu, Sharad Magar, Wenhong Fan, Elizabeth Yost, Juo Qing Guo
  • Patent number: 7351839
    Abstract: This invention provides processes for preparing compounds formula: wherein R is H, alkyl, acyl, aryl, aroyl or —C(O)R?; R? is alkyl or aryl; R1, R2, R4 and R5 are H, —OH, alkyl, cycloalkyl, alkoxy, halogen, fluorinated alkyl or alkoxy, —CN, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, acyl, aryl or aroyl; R3 is H, alkyl, cycloalkyl, alkoxy, fluorinated alkyl, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, fluorinated alkoxy, acyl, aryl, or aroyl; or a pharmaceutically acceptable salt thereof, as well as novel compounds useful in the synthesis of these compounds.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: April 1, 2008
    Assignee: Wyeth
    Inventors: Gregory S. Welmaker, Joan E. Sabalski, Michael D. Smith
  • Patent number: 7351709
    Abstract: The present invention relates to estrogen receptor ligands, and compounds and methods for treating diseases associated with excessive estrogen receptor activity. Compound of the formula I are disclosed: wherein W is O or (CR8)2, and R1 to R8, Y, and m are defined as defined herein.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: April 1, 2008
    Assignee: Wyeth
    Inventors: Paige Erin Mahaney, Michael Byron Webb, Fei Ye, Joseph Peter Sabatucci
  • Patent number: 7351730
    Abstract: This invention provides PAI-1 inhibiting compounds of Formula I: wherein: R1, R2, R3, and R4 are each H, alkyl, alkanoyl, halo, OH, aryl optionally substituted with R8, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; R5 is H, alkyl, perfluoroalkyl, aryl optionally substituted with R8, alkanoyl, aroyl optionally substituted with R8; R6 is H, alkyl, alkylaryl, benzyl optionally substituted with R8, alkanoyl, aroyl optionally substituted with R8; R7 is H, alkyl, alkylaryl, aryl optionally substituted with R8; n is 0-6; A is COOH, or an acid mimic such as tetraazole, SO3H, PO3H2, tetronic acid, etc.; R8 is H, alkyl, cycloalkyl, alkanoyl, halo, OH, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; or a pharmaceutically acceptable salt thereof; as well as pharmaceutical compositions and methods of treatment using these compounds.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: April 1, 2008
    Assignee: Wyeth
    Inventors: Scott Christian Mayer, Eric Gould Gundersen, Hassan Mahmoud Elokdah, David LeRoy Crandall
  • Publication number: 20080076801
    Abstract: The present invention provides an indolylalkylpyridin-2-amine compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: September 20, 2007
    Publication date: March 27, 2008
    Applicant: Wyeth
    Inventors: Yinfa Yan, Ping Zhou, Yi Fan, Albert Robichaud, Michael Malamas
  • Publication number: 20080076153
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Application
    Filed: August 6, 2007
    Publication date: March 27, 2008
    Applicant: Wyeth
    Inventors: Lynn Doucette-Stamm, David Bush
  • Patent number: 7348012
    Abstract: Methods and compositions for protecting avian hosts (e.g., turkeys and/or chickens) from turkey rhinotracheitis virus and/or TRT or SHS respiratory distress utilize in ovo administration of live, avirulent strains of TRTV at appropriate dosage levels on a per egg basis to provide an effective and efficient vaccination having acceptable safety and efficacy features, and additionally provides higher titers in vaccinated birds than conventionally administered vaccines.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: March 25, 2008
    Assignee: Wyeth
    Inventor: Frans Gerrit Davelaar
  • Patent number: 7348351
    Abstract: The invention formula substituted 3-alkyl and 3-arylalkyl 1H indol-1yl acetic acid derivatives which are useful as inhibitors of plasminogen activator inhibitor (PAI-1) useful for treating fibrinolytic disorders, the compounds having the structure wherein: R1,R2, R3, R4, R5, R6, and R7 are as defined herein or a pharmaceutically acceptable salt or ester form thereof.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: March 25, 2008
    Assignee: Wyeth
    Inventors: Lee Dalton Jennings, Scott Lee Kincaid
  • Patent number: 7348417
    Abstract: Methods for the purification of the macrolide moxidectin result in higher purity levels than can often otherwise be obtained. The crystalline moxidectin is then used in a wide variety of pharmaceutical and veterinary applications, including the prevention, treatment and control of parasites in plants, animals and humans.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: March 25, 2008
    Assignee: Wyeth
    Inventors: Isidoro H. Sorokin, Paola Di Raimondo, Chin-Liang Chou
  • Publication number: 20080069773
    Abstract: Novel sodium channel nucleic acids and polypeptides are disclosed herein. Methods of using the novel nucleic acids and polypeptides are also disclosed.
    Type: Application
    Filed: December 10, 2004
    Publication date: March 20, 2008
    Applicant: WYETH
    Inventors: Rodrigo Franco, Angela Hornsten
  • Publication number: 20080070268
    Abstract: The present invention provides methods for systematically identifying genes and proteins and related pathways that maximize protein expression and secretion by expression profiling analysis. The present invention further provides methods for manipulating the identified genes and proteins to engineer improved cell lines.
    Type: Application
    Filed: April 21, 2007
    Publication date: March 20, 2008
    Applicants: Wyeth, Dublin City University
    Inventors: Karin Anderson, Niall Barron, Timothy Charlebois, Martin Clynes, Dana Di Nino, Padraig Doolan, Patrick Gammell, Kathleen Kopycinski, Mark Leonard, Kevin McCarthy, Paula Meleady, Mark Melville, Martin Sinacore
  • Publication number: 20080070943
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: September 19, 2007
    Publication date: March 20, 2008
    Applicant: Wyeth
    Inventors: Derek Cole, Ronald Bernotas
  • Patent number: RE40183
    Abstract: The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula wherein R, X, R5 and R6 are defined in the specification. The compounds of the invention are useful as broad spectrum antibiotics.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: March 25, 2008
    Assignee: Wyeth Holdings Corporation
    Inventors: Joseph J. Hlavka, Phaik-Eng Sum, Yakov Gluzman, Ving J. Lee, Adma A. Ross